secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2025-12-12T23:59:59+00:00
Accession:  0001815776-25-000077
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

LENZ Therapeutics addresses FAERS report of retinal tear in VIZZ patient with pre-existing risk factors
--------------------------------------------------------------------------------

- FAERS report describes retinal tear in a patient using VIZZ (aceclidine ophthalmic solution) 1.44%.
- Patient had significant retinal pathology history: lattice degeneration, prior laser, previous tear; no recent peripheral exam.
- Independent retina specialists note multiple pre-existing risk factors making spontaneous retinal events more likely.
- Company states this initial report does not alter current safety expectations for VIZZ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000181577625000077/0001815776-25-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000181577625000077/lenz-20251212.htm
  HTML page:      https://secwatch.observer/filing/0001815776-25-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer